Date:2/18/2009

ents. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding the timing of ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, the timing of CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure, our ability to generate efficacy and safety data required for the marketing approval of ATPace, and the effects of the initial doses of ATPace. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.'/>"/>

SOURCE Cordex Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Cordex Pharma Sets Fourth Quarter 2008 Program Update Call
2. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
3. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
4. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
5. National Pharmaceutical Council on Economic Stimulus Package: Comparative Effectiveness Research Funding Should Target Improvements in Quality of Patient Care
6. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
7. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
8. WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
9. Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
10. Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
11. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast